Will Customs Seize Your Peptides?

The honest answer to whether a border will stop a given parcel is that nobody can tell you, and no agency publishes a per-shipment rate. What is written down, in public and in detail, is the process a stopped shipment enters and the outcomes available at the end of it. That is worth knowing in advance, because the process moves on short timers and the first document a recipient sees is usually a notice with a deadline already running. This page describes the rules and the outcomes and nothing else. It offers no guidance on labelling, declaring, routing, splitting or presenting a shipment, and no part of it should be read as a way to make an examination less likely. It is educational context, not legal advice and not medical advice.

Who stops the parcel, and who decides its fate

Two agencies share the job and each does a different half. Customs and Border Protection has physical custody and does the looking. The FDA decides admissibility for articles under its jurisdiction, and its own manual is blunt about the division: FDA personnel are not to examine personal baggage, and that responsibility rests with CBP. For international mail, the manual describes a CBP officer at the mail division examining a parcel and setting it aside when it appears to contain a drug, a biologic or a device, when the FDA has asked that something be held, or when the article appears to represent a health fraud or an unknown risk to health. Parcels set aside that way are then audited by the FDA, and anything detained stays with CBP until it is either released or refused entry.^[1]

The legal trigger is the appearance of a violation

Section 801(a) of the Federal Food, Drug, and Cosmetic Act is the operative provision, and the agency's manual reproduces it. It says that if it appears from the examination of samples or otherwise that an article was made under insanitary conditions, is forbidden or restricted in sale in the country it came from, or is adulterated, misbranded or in violation of the new drug section, then the article shall be refused admission. Two words carry most of the weight. Appears is the standard, not proves. And otherwise means a laboratory result is not required at all. The manual makes the second point explicitly: a detention can rest on a very brief examination if that furnishes evidence creating the appearance of a violation, and where no sample is examined there should instead be substantial documentary evidence, such as a violation in a previous shipment of the same product from the same firm. This is not a criminal standard. It is an administrative threshold, and it sits low by design.^[1]

The detention notice and the response window

The first document is a notice. Under 21 CFR 1.94, when it appears an article may be subject to refusal of admission, or is a drug that may be subject to destruction, the division director must give the owner or consignee written or electronic notice to that effect stating the reasons, and that notice must specify a place and a period of time during which the owner or consignee has an opportunity to introduce testimony. In practice it arrives as a Notice of FDA Action marked as detained, listing the charges: the specific sections the entry appears to violate and a short statement of how. The manual describes the customary window as 10 working days following the date of detention shown on the notice, extendable where circumstances genuinely require it. Testimony does not have to be a hearing in a room: the manual lists telephone, fax, mail, email and personal appearance, with the compliance officer required to document whatever comes in. It is confined to matters relevant to admissibility.^[1]

Refusal, and then export or destruction

If the responsible office weighs the evidence and still finds the articles violative or apparently violative, it may refuse admission and issue a Notice of Refusal of Admission, restating the charges from the detention notice. What happens next turns on what the article is and what it is worth. The general statutory rule is that a refused article must be exported under supervision within 90 days of the date of notice of refusal, or within such additional time as the regulations provide, and if it is not exported it is destroyed. For mail shipments the manual describes the notice arriving in one of two forms: refusal of admission with return to sender, or refusal of admission and administrative destruction. The second form is the one worth reading twice. A 2012 statute, FDASIA, gave the agency authority to destroy, with no opportunity for export, any refused drug valued at $2,500 or less, or such higher figure as may be set by regulation. The agency implemented that authority in April 2016, and the final rule on administrative destruction was published in May 2024 and took effect that July. On its own summary of the authority, the agency says the products it reaches are offered for import through international mail and express couriers, and that where it does not find a drug or device meets the criteria for personal importation, it may exercise destruction authority. Most personal-scale shipments sit comfortably under that value line.^{[1, 3]}

The standing instruction: detention without physical examination

There is also a mechanism that removes the need to examine anything. Import Alert 66-41 is a standing instruction titled Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S., and the products it covers are not FDA-approved. Its stated rationale is that unapproved new drugs have not been reviewed for safety or effectiveness, so there is no way to know whether they work for their intended use, whether they are made to consistent quality, or whether their labels are accurate, and that such drugs have resulted in patient harm. Operationally, divisions may detain without physical examination the identified products from firms on the alert's red list. The consequence for anyone on the receiving end is a shift in burden. To secure release of an individual shipment caught by the alert, the owner, consignee or another responsible party is expected to provide evidence that the shipment does not contain unapproved new drug products. That is harder to demonstrate than it sounds, and it is the recipient's job rather than the government's.^[4]

Why the personal-importation argument does not reach research material

The argument people reach for is the personal importation policy, and it does exist. The agency's consumer-facing page on it opens somewhere less comfortable than the argument assumes: in most circumstances, it says, it is illegal for individuals to import drugs or devices for personal use, because products bought from other countries often have not been approved by the FDA, and a drug approved elsewhere that is an unapproved new drug in the United States is illegal to import. The policy is a discretionary lane inside that position rather than an exception to it, and the manual warns that its own leniency should not be read as a licence for individuals to bring in such shipments. The more permissive route for an unapproved intended use asks that the consumer affirm in writing that the product is for personal use, that the quantity is generally not more than a three month supply, and that they either give the name and address of a doctor licensed in the United States responsible for their care with the product or show evidence that it continues a course begun in a foreign country. Every one of those conditions presumes a patient, a prescriber and an existing course of care. Material sold as research use only, by the wording of its own label, asserts none of them. The lane is written around a fact pattern that research-use labelling does not describe, and the manual creates no research-use category beside it.^{[1, 2]}

Commercial and promotional shipments sit outside it entirely

There is a second exclusion, and it is the one that catches most online orders. The manual places commercial and promotional shipments outside the personal importation procedures altogether, and says whether a shipment counts as commercial may be judged on the type of product, any accompanying literature, the size, the value and the destination. It also names quantity as a signal, treating a supply beyond roughly what one person might use in three months as suggesting commercial distribution. Non-commercial shipments are described as goods personally carried, goods sent by a personal non-commercial representative of the recipient, and goods sent from a foreign medical facility where the person received care. The agency's own list of circumstances in which it would refuse a personal importation names a product on an import alert for previous violations, a shipment that appears intended for commercial distribution, a product that appears to present a serious risk to health, and an article that appears to represent a health fraud. Import Alert 66-41 puts the same point in one sentence: commercial or promotional shipments, and products subject to detention without physical examination, are generally not amenable to the use of enforcement discretion. An order placed on a website and dispatched by a seller is a commercial shipment on its face, whoever receives it and in whatever quantity.^{[1, 2, 4]}

Where seized material actually ends up

When European controlling agencies stop suspect injectable peptide preparations, the material goes to an official medicines control laboratory for identification. Analysts at the Belgian institute publishing that work described a screening method covering 25 different peptides, assembled from substances already detected in illegal and counterfeit products seized by European countries, and named the national medicines agency and customs as the parties sending the samples. The seizures are not hypothetical, and what turns up in these shipments is a published literature rather than a rumour.^[5]

What this page deliberately does not tell you

Three limits, stated plainly. First, this is a description of rules and outcomes, and it contains no advice about how a package should be labelled, declared, valued, split, routed or timed. We do not publish that, and nothing above should be read as a hint toward it. Second, none of this is legal advice. Outcomes vary by port, officer, product and the documentary history attached to a seller, and anyone facing a real notice with a live deadline should speak to a lawyer who handles import matters rather than a website. Third, this page is about logistics, not legality. Whether a compound is lawful to possess where you live is a separate question, covered at are peptides legal and, peptide by peptide, at is my peptide legal in 2026. A parcel can be refused entry for a substance that is perfectly lawful to hold once inside the country, because admissibility and possession run on different rules.

The one-line version

A stopped shipment produces a notice with a short window to introduce testimony, then a refusal, then either return to sender, export under supervision within 90 days, or destruction with no export option where the article is a drug valued at $2,500 or less. The personal importation lane people reach for was written around a patient with a named prescriber and an existing course of care, which research-use-only material does not have by the terms of its own label. The rules themselves are unusually clear. The awkwardness is that they were written for a situation this market does not resemble, and sitting outside an exception is not the same thing as sitting inside a loophole.

References & sources

1. U.S. FDA, Regulatory Procedures Manual, Chapter 9: Import Operations and Actions (MAN-000012, version 05, March 2024). Subchapter 9-2 covers personal importations, the personal-use conditions and the commercial or promotional exclusion; 9-3 reproduces the section 801(a) grounds for refusal, states the 21 CFR 1.94 notice requirement, sets out the evidence required for detention and the customary 10 working days to introduce testimony, and lists the acceptable forms of testimony; 9-4 covers refusal of admission and administrative destruction for mail shipments of drugs valued at $2500 or less; the 90-day export-or-destroy rule appears at subchapter 9-11.
2. U.S. FDA, Personal Importation (Import Program, Import Basics; content current as of 18 August 2025). States that in most circumstances it is illegal for individuals to import drugs or devices for personal use because such products often have not been approved by the FDA, sets out the conditions for a more permissive decision including the written affirmation of personal use, the generally three month quantity limit and the U.S.-licensed doctor or continuation-of-treatment evidence, and lists the circumstances in which a personal importation would be refused.
3. U.S. FDA, Administrative Destruction Authority (Import Program, Import Basics; content current as of 16 March 2026). Records that the 2012 Food and Drug Administration Safety and Innovation Act gave the agency authority to destroy, without an opportunity for export, any refused drug valued at $2,500 or less; that the authority was implemented on 4 April 2016; that the final rule on administrative destruction was published on 31 May 2024 and took effect on 1 July 2024; that the products it reaches are offered for import through international mail and express couriers; and that where the agency does not find a drug or device meets the criteria for personal importation, it may exercise destruction authority.
4. U.S. FDA, Import Alert 66-41, Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. (published 16 July 2026; revision dated 19 May 2026). Divisions may detain without physical examination the identified products from firms on the red list; the owner, consignee or other responsible party seeking release of an individual shipment should provide evidence that the shipment does not contain unapproved new drug products; commercial or promotional shipments, and products subject to detention without physical examination, are generally not amenable to the use of enforcement discretion.
5. Vanhee C, Janvier S, Desmedt B, Moens G, Deconinck E, De Beer JO, Courselle P. Analysis of illegal peptide biopharmaceuticals frequently encountered by controlling agencies. Talanta 142:1-10 (2015). Suspected peptide preparations are analysed at the Belgian official medicines control laboratory at the request of the national medicines agency and customs; the published LC-MS/MS screening method covers 25 peptides drawn from substances already detected in illegal and counterfeit products seized by European countries.